



NEWS RELEASE

Evolus to Participate in November Conferences

11/2/2022

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in two investment conferences in November.

Event: Stifel 2022 Healthcare Conference
Date: Tuesday, November 15, 2022
Time: 8:35-9:05 am ET

Event: 5th Annual Evercore ISI HealthCONx Conference
Date: Wednesday, November 30, 2022
Time: 11:45-12:05 pm ET

Audio webcasts of these events will be available on the investor relations section of Evolus' website at www.evolus.com. Replays of the webcasts will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com and follow us on [LinkedIn](#), [Twitter](#), [Instagram](#) or [Facebook](#).

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor/Media Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: 949-966-1798

Email: **david.erickson@evolus.com**

Source: Evolus